Dutasteride and Tadalafil Interaction: Safety, Mechanism, and Clinical Guidance

Dutasteride (brand name Avodart, a dual 5-alpha reductase inhibitor) and tadalafil (brand name Cialis, a phosphodiesterase type 5 inhibitor) do not have a clinically significant pharmacokinetic interaction with each other. Both are FDA-approved for men with benign prostatic hyperplasia (BPH), each at its own labeled dose, and both are also used off-label in other contexts (dutasteride for hair loss, tadalafil on demand for erectile dysfunction). This article covers the two-drug pairing only, in adult men, for BPH-related use unless stated otherwise. Individual dosing decisions should be made with a prescriber who knows the patient's cardiovascular history, liver and kidney function, and full medication list.

At a glance

• Pharmacokinetic interaction between dutasteride and tadalafil: none established as clinically significant
• Shared metabolic pathway: both are CYP3A4 substrates, but tadalafil is only a weak CYP3A4 inhibitor at therapeutic doses
• Combined use in BPH: an accepted, guideline-consistent strategy, though the pivotal CombAT trial tested dutasteride with tamsulosin, not tadalafil
• Additive hypotension: not established between dutasteride and tadalafil alone; the recognized risk is tadalafil plus an alpha-blocker
• Dutasteride elimination half-life: reported at roughly 5 weeks at steady state (verify current label wording)
• Tadalafil dose approved for BPH: 5 mg once daily
• PSA monitoring: unchanged by adding tadalafil; the dutasteride PSA correction factor still applies

The direct answer

Current FDA prescribing information for dutasteride and for tadalafil does not identify each other as a contraindicated or dose-adjusting combination. The two drugs are metabolized through overlapping but not competing pathways, they act on different physiological targets in the prostate, and BPH treatment guidelines support using a 5-alpha reductase inhibitor alongside a second agent that addresses smooth-muscle tone. The unresolved question for an individual patient is not whether dutasteride and tadalafil interact, but whether a third drug, most often an alpha-blocker, is also being used, because that combination carries a real and well-documented orthostatic hypotension risk that this pairing alone does not.

Why they don't compete for metabolism

Dutasteride is cleared primarily through hepatic CYP3A4 (with a smaller role for CYP3A5). Tadalafil is also a CYP3A4 substrate, but at approved doses it is only a weak inhibitor of that enzyme, not a driver of clinically meaningful drug accumulation. The FDA label for dutasteride flags concern with potent CYP3A4 inhibitors such as ketoconazole or ritonavir, not with tadalafil. The reverse direction also holds: dutasteride has no known inducing or inhibiting effect on CYP3A4 and is not expected to change tadalafil clearance.

Both drugs are also highly protein bound (dutasteride is bound at a very high percentage to albumin; tadalafil is bound to a lesser but still substantial degree). Displacement interactions generally require both high binding affinity and a narrow therapeutic index in at least one of the drugs. Dutasteride's long elimination half-life (commonly cited as roughly 5 weeks at steady state, though this figure should be checked against the current label text before it is used in patient-facing material) reflects its lipophilicity and protein binding, not a competitive interaction with tadalafil.

What this means in one paragraph: Dutasteride and tadalafil share a metabolic enzyme but do not meaningfully compete for it, they have no established pharmacodynamic antagonism, and current FDA labeling does not require a dose adjustment for either drug when they are used together for BPH. The clinically relevant caution in this drug pairing is not the two drugs themselves but the addition of a third agent, an alpha-blocker, which introduces an additive hypotension risk with tadalafil that dutasteride does not share. This distinction, not the existence of an interaction, is what should guide monitoring.

Why they're prescribed together for BPH

Dutasteride blocks type 1 and type 2 5-alpha reductase, lowering serum dihydrotestosterone and shrinking prostate volume over months. This addresses the static, mechanical component of obstruction. Tadalafil inhibits phosphodiesterase type 5 in prostatic and bladder-neck smooth muscle, relaxing tone through the cyclic GMP pathway. This addresses the dynamic component of obstruction. The two mechanisms are complementary rather than competing, which is the pharmacological rationale for combining them.

The evidence base for combining a 5-alpha reductase inhibitor with a second BPH agent is strongest for dutasteride plus tamsulosin, established in the large CombAT trial, which compared combination therapy against each drug alone in men with moderate to severe symptoms and enlarged prostates. That trial did not test tadalafil. Tadalafil 5 mg daily has its own FDA approval for BPH symptoms based on separate randomized trials, and combination studies of PDE5 inhibitors with 5-alpha reductase inhibitors have reported greater symptom improvement than 5-ARI monotherapy alone. The size and precision of that added benefit vary across studies and specific effect estimates from any single meta-analysis should be confirmed against the primary paper before being quoted to a patient.

What actually needs monitoring: hypotension, and mainly with a third drug

Tadalafil causes mild systemic vasodilation; average blood pressure changes with 5 mg daily dosing are small. Dutasteride has no direct vascular effect. As a two-drug regimen, dutasteride plus tadalafil is not established to cause clinically meaningful additive hypotension in patients with normal baseline blood pressure.

The scenario that does require attention is triple therapy: dutasteride plus tadalafil plus an alpha-blocker (tamsulosin, silodosin, alfuzosin, or similar). Alpha-blockers and PDE5 inhibitors both reduce vascular smooth muscle tone, and combining them can produce symptomatic orthostatic drops, particularly within a few hours of dosing. For patients on all three drugs, reasonable practice, consistent with general BPH management guidance from the American Urological Association, is to:

• Stabilize the alpha-blocker dose before adding tadalafil
• Favor a more uroselective alpha-blocker where clinically appropriate
• Advise patients to rise slowly from sitting or lying positions
• Check standing blood pressure at follow-up if the patient reports dizziness or lightheadedness

Readers should confirm the current AUA BPH guideline language directly, since guideline documents are periodically amended: AUA benign prostatic hyperplasia guideline.

Sexual side effects move in opposite directions

Dutasteride's FDA label lists sexual side effects including erectile dysfunction, decreased libido, and ejaculatory disorders occurring more often than with placebo during the first months of therapy, with rates generally declining over time. Tadalafil, by contrast, is used specifically to support erectile function. In men who develop treatment-emergent erectile dysfunction on dutasteride, adding tadalafil is a plausible way to offset that side effect, and combination studies have reported better preserved erectile-function scores with a PDE5 inhibitor added to a 5-ARI compared with the 5-ARI alone. The exact magnitude of that benefit varies by study population and should not be quoted as a fixed number without checking the specific trial.

Both drugs can independently affect ejaculation: dutasteride through reduced prostatic secretions, tadalafil through occasional reports of altered ejaculatory timing. Patients should be told these effects can occur separately and may not fully resolve with either drug alone.

Readers can review the FDA dutasteride label directly for the current adverse-event tables rather than relying on secondhand percentages: Avodart (dutasteride) prescribing information.

PSA monitoring does not change

Dutasteride suppresses serum PSA by roughly half after about 6 months of continuous use, which is why the standard practice is to apply a correction factor (commonly a doubling) when interpreting PSA for cancer screening in men on a 5-alpha reductase inhibitor. Tadalafil has no known effect on PSA. Adding or stopping tadalafil does not change the correction approach for a patient already on dutasteride. Any PSA rise that exceeds the corrected threshold still warrants urological evaluation regardless of concomitant PDE5 inhibitor use. A baseline PSA before starting dutasteride, a repeat at around 6 months to confirm expected suppression, and routine annual monitoring thereafter remain the reasonable framework, applied by the prescribing clinician.

Interactions that matter with each drug individually, even though this pairing is low-risk

Dutasteride: Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, and similar drugs) can raise dutasteride exposure. Given its long half-life, accumulation from a strong inhibitor could persist for an extended period after the inhibitor is stopped. Verify current interaction language directly against the FDA label rather than a secondary summary: Avodart prescribing information.

Tadalafil: Nitrates (nitroglycerin, isosorbide mononitrate or dinitrate, and recreational nitrites) are an absolute contraindication because of the risk of severe, potentially life-threatening hypotension. Alpha-blockers require staged initiation as described above. Strong CYP3A4 inhibitors can require a reduced tadalafil dose, and strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine) may reduce tadalafil's effect. See the current Cialis label for exact dose-adjustment thresholds by checking the manufacturer's official prescribing information.

Practical dosing notes

For BPH combination therapy, the typical regimen is dutasteride 0.5 mg once daily (with or without food, any time of day) alongside tadalafil 5 mg once daily. No timing separation between the two doses is required by either label. For men using dutasteride off-label for hair loss who also take tadalafil on demand for erectile dysfunction at higher intermittent doses, the same nitrate and alpha-blocker precautions for tadalafil apply, independent of the dutasteride.

Patients should be told that dutasteride's effects on prostate volume and symptoms build over 3 to 6 months, while tadalafil's effect on urinary symptoms can appear within 1 to 2 weeks. Setting this expectation reduces the chance a patient stops the 5-ARI too early, believing it is not working.

When this combination should be avoided or reassessed

• Known hypersensitivity to either drug or its components
• Women of childbearing potential or pregnant women should not use dutasteride, which carries a pregnancy contraindication because of teratogenic risk to a male fetus; tadalafil is not indicated in women
• Any current nitrate use, in any form, is an absolute contraindication for tadalafil
• Unstable angina, a recent myocardial infarction, significant heart failure, uncontrolled arrhythmia, or low baseline blood pressure warrant a cardiology-informed decision before starting a PDE5 inhibitor
• A history of non-arteritic anterior ischemic optic neuropathy is a relative contraindication for tadalafil
• Moderate to severe hepatic impairment requires dose caution or avoidance of tadalafil, and increases theoretical accumulation risk for dutasteride
• Significant renal impairment (CrCl below 30 mL/min) generally calls for a lower starting tadalafil dose with careful titration; dutasteride has no specific renal dose adjustment

Chest pain, fainting, sudden vision or hearing changes, or a prolonged erection lasting more than 4 hours after taking tadalafil are reasons to seek urgent medical care rather than waiting for a scheduled follow-up.

Evidence boundary: what is established, what is plausible, what is not

Established: FDA labeling for both drugs does not flag a pharmacokinetic interaction between dutasteride and tadalafil requiring dose adjustment. Dutasteride's mechanism (5-alpha reductase inhibition, DHT suppression, PSA suppression) and tadalafil's mechanism (PDE5 inhibition, smooth-muscle relaxation) are independently well characterized. The alpha-blocker plus PDE5 inhibitor hypotension risk is a recognized concern addressed in BPH management guidance.

Plausible but not rigorously quantified on this page: The exact magnitude of added IPSS improvement, or of erectile-function preservation, when tadalafil is added to dutasteride specifically (as opposed to 5-ARIs as a class) has been reported in combination-therapy studies, but the precise effect sizes circulating in secondary summaries should be verified against the primary trial or meta-analysis before being presented as fixed numbers.

Not established: A direct, dedicated head-to-head trial of dutasteride plus tadalafil versus dutasteride plus tamsulosin. The strongest direct-comparison evidence (CombAT) tested tamsulosin, not tadalafil, so claims of equivalence between the two combination strategies are an extrapolation, not a demonstrated result.

Evidence-status assessment: dutasteride plus tadalafil

Common questions this evidence can actually answer

Do I need to space out dutasteride and tadalafil doses? No. Neither label requires timing separation between the two drugs.

Will tadalafil make dutasteride less effective at shrinking the prostate? No mechanism supports this. Tadalafil does not inhibit 5-alpha reductase and is not known to affect DHT suppression.

Does tadalafil change how I should interpret my PSA? No. The correction factor used for men on dutasteride is unrelated to tadalafil use.

Is it safe to add tamsulosin to dutasteride and tadalafil? This is the combination that actually needs monitoring. Stabilize the alpha-blocker first, watch for dizziness on standing, and confirm current guidance with the prescriber rather than assuming the two-drug safety profile extends automatically to three drugs.

Can women use this combination? No. Dutasteride carries a pregnancy contraindication due to fetal risk, and tadalafil is not approved for use in women.

References

• U.S. Food and Drug Administration. Avodart (dutasteride) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021319s032lbl.pdf
• American Urological Association. Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms guideline. https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-(bph)-guideline

This article summarizes drug labeling and general BPH treatment literature for educational purposes. Specific trial citations, effect sizes, and adverse-event percentages referenced above as "plausible" or requiring verification have not been independently confirmed against their primary sources in this draft and should be checked before clinical or patient-facing use. This is not a substitute for individualized medical advice.